Kam

Kamada is a vertically integrated global biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty plasma-derived protein therapeutics. The company's portfolio includes several FDA-approved products such as Glassia for Alpha-1 Antitrypsin (AAT) deficiency and KEDRAB for rabies post-exposure prophylaxis. Kamada leverages a proprietary platform technology for the high-purity extraction and purification of proteins from human plasma. Beyond its core therapeutic business, the company operates a significant distribution segment in Israel, providing a wide range of third-party pharmaceutical products. Kamada is currently advancing a robust pipeline, including an inhaled formulation of AAT for the treatment of hereditary emphysema.